FDA Approves Aethlon Medical's Protocol Amendment For COVID-19 Trial

(RTTNews) - The U.S. Food and Drug Administration has approved an amendment to the protocol of ongoing clinical trial investigating the Aethlon Hemopurifier for patients with severe COVID-19, Aethlon Medical Inc. (AEMD) said in a statement on Monday.

The company stated that the approval eliminates the requirement for previous dialysis treatment, potentially enabling accelerated enrollment in the ongoing clinical study.

The Aethlon Hemopurifier is a therapeutic blood filtration system that can bind and remove life-threatening viruses and harmful exosomes from blood.

Aethlon is currently evaluating the safety and feasibility of the Hemopurifier in an active Early Feasibility Study, analogous to a Phase 1 clinical trial for a drug or biologic, which is designed to enroll up to 40 severe COVID-19 patients.

For More Such Health News, visit rttnews.com